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Abstract 
Pancreatic ductal adenocarcinoma is the most common 
malignant tumor of the pancreas. The remaining 
pancreatic tumors are a diverse group of pancreatic 
neoplasms that comprises cystic pancreatic neoplasms, 
endocrine tumors and other uncommon pancreatic 
tumors. Due to the excellent soft tissue contrast reso-
lution, magnetic resonance imaging (MRI) is frequently 
able to readily separate cystic from noncystic tumors. 
Cystic tumors are often easy to diagnose with MRI; 
however, noncystic non-adenocarcinoma tumors may 
show a wide spectrum of imaging features, which 
can potentially mimic ductal adenocarcinoma. MRI is 
a reliable technique for the characterization of pan-
creatic lesions. The implementation of novel motion-
resistant pulse sequences and respiratory gating 
techniques, as well as the recognized benefits of MR 
cholangiopancreatography, make MRI a very accurate 
examination for the evaluation of pancreatic masses. 
MRI has the distinctive ability of non-invasive assessment 
of the pancreatic ducts, pancreatic parenchyma, nei-
ghbouring soft tissues, and vascular network in one 
examination. MRI can identify different characteristics 
of various solid pancreatic lesions, potentially allowing 
the differentiation of adenocarcinoma from other benign 
and malignant entities. In this review we describe the 
MRI protocols and MRI characteristics of various solid 
pancreatic lesions. Recognition of these characteristics 
may establish the right diagnosis or at least narrow the 
differential diagnosis, thus avoiding unnecessary tests or 
procedures and permitting better management.
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other solid pancreatic lesions occur. Less common solid 
primary pancreatic tumors and non-neoplastic disease 
processes that may be diagnosed with relatively high 
specificity employing magnetic resonance imaging 
(MRI). The radiologist must be familiar with their MRI 
appearance to correctly diagnose them, or suggest them 
in the differential diagnosis when appropriate, since it 
may change substantially the approach, prognosis and 
patient management.
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INTRODUCTION
Pancreatic ductal adenocarcinoma is the most common 
malignant tumor of the pancreas, accounting for 
85%-90% of all malignant pancreatic tumors and is the 
4th most common cause of cancer death worldwide[1]. 
The remaining 10%-15% of pancreatic tumors is 
a varied group of neoplasms that comprises cystic 
pancreatic neoplasms, endocrine tumors and other 
uncommon pancreatic tumors. Magnetic resonance 
imaging (MRI) is reliable for the characterization of 
solid and cystic pancreatic lesions. Due to the excellent 
soft-tissue contrast resolution, MRI is able to readily 
separate cystic from noncystic tumors. Cystic tumors are 
frequently easier to diagnose since they often possess 
typical imaging findings allowing an accurate and 
reliable prospective diagnosis. Noncystic noncarcinoma 
tumors may show a wide spectrum of imaging features, 
which most often are distinct from the features of 
ductal adenocarcinoma. Infrequently they may possess 
features that simulate carcinoma, and therefore clinical 
history and laboratory parameters are always important 
to be aware of. In this review we describe the typical 
MRI characteristics of various solid pancreatic lesions, 
which will aid in differentiation of adenocarcinoma from 
other benign and malignant entities. Recognition of these 
characteristics often may establish the right diagnosis or 
at least narrow the differential diagnosis, which will allow 
better patient management and avoid unnecessary tests 
or procedures. 
We herein describe the typical MRI findings of ductal 
adenocarcinoma, of less common solid primary pancr-
eatic tumors, and of non-neoplastic disease processes 
that may simulate ductal adenocarcinoma. 
CLASSIFICATION OF PANCREATIC 
TUMORS
According to the World Health Organization classifi-
cation, pancreatic tumors are classified depending on 
the cell lineage they arise from. The tumors may have 
an epithelial or nonepithelial origin. 
Tumors with epithelial origin include the exocrine 
pancreas: (1) ductal cells, including ductal adeno-
carcinoma with its different histopathological variants, 
and mucinous and serous cystic tumors; (2) acinar 
cells, including acinar cell carcinoma (ACC) and mixed 
acinar-endocrine carcinoma; or (3) uncertain origin, 
including solid pseudopapillary tumor (SPT) and pancre-
atoblastoma or the endocrine pancreas (functioning and 
nonfunctioning tumors).
The nonepithelial tumors include neoplasms such 
as primary lymphoma and tumors of mesenchymal cell 
origin (hemangioma, lymphangioma, sarcoma, lipoma, 
etc.).
There are also nonpancreatic tumor lesions in origin 
that might involve the pancreas, including malignant 
lesions such as metastasis or secondary lymphoma, and 
benign lesions such as intrapancreatic splenule.
MRI EVALUATION OF THE PANCREAS
MRI is a reliable technique for the characterization of 
pancreatic lesions. The implementation of novel motion-
resistant pulse sequences and respiratory gating 
techniques, as well as the recognized benefits of MR 
cholangiopancreatography, make MRI a very accurate 
examination for the evaluation of pancreatic masses. 
MRI has the distinctive ability of non-invasive assess-
ment of the pancreatic ducts, pancreatic parenchyma, 
neighbouring soft tissues, and vascular network in one 
examination. 
MRI of the pancreas should be performed with state 
of the art scanners using high field strength (1.5T or 
3T) units[2-4] with phased-array torso coils and parallel 
imaging to maximize signal to noise ratio and permit for 
superior spatial resolution and faster acquisition times.
3T systems allow higher spatial resolution and 
provide the highest post-contrast imaging quality and 
temporal resolution of the pancreas, which is important 
when evaluating small focal pancreatic lesions[4], and 
looking for vascular involvement or encasement. 
The typical MRI protocol for the assessment of the 
pancreas commonly includes coronal and transverse T2-
weighted single-shot echo train spin echo (SS-ETSE), 
transverse T2-weighted fat suppressed fast spin echo 
or SS-ETSE, transverse in-phase and out-of-phase T1-
weighted spoiled gradient echo (GRE), and transverse 
T1-weighted fat suppressed three-dimensional (3D) 
GRE images, obtained before and after contrast injection 
during the late arterial, portal-venous and interstitial 
phases. Magnetic resonance cholangiopancreatography 
(MRCP) is routinely added to abdominal protocols to 
assess ductal obstruction, dilatation or luminal outline. 
This sequence combination provides comprehensive 
evaluation of a full range of pancreatic disease processes.
T2-weighted SS-ETSE sequences such as half-
Fourier acquisition snapshot turbo spin-echo offer 
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anatomic display of the common bile duct (CBD) and 
pancreatic duct on coronal and transverse plane images. 
This sequence is important to evaluate fluid content, 
which most often allows clear separation of cystic and 
solid content lesions, as well as complications such as 
the assessment of the complexity of pancreatic fluid 
collections.
Pre- and post-contrast T1-weighted GRE sequences 
are typically obtained as a fat-suppressed 3D-GRE 
technique, allowing high-quality dynamic imaging of 
the pancreas. The main benefits of these sequences 
include the ability to obtain thinner slices (2-3 mm) and 
to perform multiplanar imaging, essential to assess and 
characterize focal pancreatic masses with < 1 cm in size 
and to evaluate diffuse pancreatic disease[3,5-10]. 
3D MRCP images are obtained in an oblique coronal 
projection following the plane of the main pancreatic 
duct, with the complementary benefit of being able to 
generate multiplanar maximum intensity projection and 
volume rendering imaging. This approach delineates 
longer segments of the pancreatic duct. MRCP depicts 
well the biliary and pancreatic ducts allowing optimal 
evaluation of ductal contour and dilatation, as well as 
abnormal duct pathways[7-9]. The combination of tissue 
imaging sequences and MRCP generate comprehensive 
information on pancreatic disease.
For the diagnosis of biliary disease, the secretin 
enhanced MRCP is routinely performed as part of the 
workup of patients with known or suspected pancreatic 
disease such as acute and chronic pancreatitis, con-
genital variants of the pancreaticoduodenal junction, 
and intraductal papillary mucinous neoplasms and 
follow-up of patients after pancreatectomy, in many 
centers. Secretin is well tolerated, and side effects are 
rarely seen[11-13]. 
MRI is a non-ionizing cross-sectional imaging method 
with a safer intra-venous contrast profile in compa-
rison to computed tomography (CT). This is especially 
important in patients at higher risk of radiation injury 
(e.g., younger patients) especially those requiring 
repeated imaging follow-up. 
Some gadolinium based contrast agents (GBCAs) 
are associated with nephrogenic systemic fibrosis. Avoid­
ance of GBCAs exposure is the best approach for high-
risk patients[14] including patients with acute or advanced 
chronic kidney disease. Also, is has been reported that 
the incidence of immediate hypersensitivity reactions 
to MR GBCAs was 0.079%, and the recurrence rate 
of hypersensitivity reactions was 30% in patients with 
prior reactions[15]. It is a very low percentage if we 
compare it to iodinate contrast media but however it 
should be considered.
New motion-resistant MRI techniques provide 
adequate images even in patients that are not able to 
suspend respiration[16]. Preliminary studies demonstrated 
that in patients who unable to suspend respiration, new 
imaging techniques for MRI, such as radial 3D-GRE 
acquired in a free breathing fashion, may be useful for 
pancreatic MR imaging and aid the radiologist in the 
detection and characterization of pancreatic focal lesions. 
Normal pancreatic parenchyma displays high T1 
signal intensity due to the presence of aqueous pro-
tein[3,4], which is accentuated on fat-suppressed GRE 
sequences. The normal pancreas typically shows uniform 
hyperintense enhancement on arterial phase images, 
fading overtime to become isointense to the liver on 
interstitial phase images (Figure 1)[6,17].
In the elderly, the high T1 signal intensity of the 
pancreas may be diminished and be lesser than that 
of the liver, reflecting fibrosis resultant from the aging 
process[5].
Pancreatic ductal adenocarcinoma
Ductal adenocarcinoma is the most common malignant 
pancreatic neoplasm and accounts for almost 90% of all 
malignant pancreatic tumors. Males are affected twice as 
often as women and the peak age of occurrence is in the 
7th to 8th decades of life[18]. At clinical presentation, 2/3 of 
patients have an advanced tumor stage. This may justify 
why pancreatic adenocarcinoma shows a poor prognosis, 
with a 5-year survival rate of 5%[19]. Despite advances in 
patient management and new chemotherapy regimens, 
surgery remains the only curative treatment[19]. 
The appearance of the typical ductal adenocarcinoma 
is an irregular, small focal solid mass (2-3 cm) without 
necrosis or hemorrhage. It is a heterogeneous and 
poorly enhancing mass with a tendency for local infiltr­
ation, including vascular encasement.
Near 60%-70% of ductal adenocarcinomas of the 
pancreas involve the pancreatic head, 10%-20% are 
found in the body and 5%-10% in the tail. Diffuse 
pancreatic involvement occurs in 5% of the cases[20]. 
Spin-echo images are limited in the detection of 
pancreatic adenocarcinoma. On T2-weighted images, 
tumors are usually slightly hypointense relative to the 
background pancreatic parenchyma and consequently 
challenging to visualize. Ductal adenocarcinomas 
appear as low signal intensity lesions on noncontrast 
fat-suppressed T1-weighted images and usually well 
delineated from normal background pancreas, which is 
high in signal intensity[17,21-24]. 
Detection of adenocarcinoma is better performed on 
the arterial phase images, where the lesion will enhance 
to a lesser degree than the adjacent background 
pancreas (Figures 2 and 3), due to the abundant fibrous 
stroma and scarce tumor vascularity[23]. The increased 
volume of the extracellular space and the venous drain-
age of tumors compared to normal pancreatic tissue are 
responsible for the near isointense appearance of ductal 
adenocarcinoma on the interstitial phase[23]. 
In general, large pancreatic tumors tend to persist 
low in signal intensity (Figure 2) on interstitial phase 
images, whereas the signal intensity of smaller tumors 
is more variable and may range from hypointense to 
minimally hyperintense on this phase (Figure 3).
Obstruction of the main pancreatic duct by the 
pancreatic adenocarcinoma, which may be seen even 
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levels are unique to ductal adenocarcinoma and allow 
correct diagnosis with high accuracy. 
Although it is non­specific, obstruction of the main 
pancreatic duct is one of the most important signs of 
ductal adenocarcinoma. The concurrent dilatation of 
the pancreatic and hepatic duct may frequently occurs 
when the pancreatic cancer develops in the cephalic 
region, thus depicting the so called “double duct sign”, in 
some cases this may be the only sign, if the pancreatic 
tumor is very small. Possible differential diagnosis in this 
case includes an acute or chronic papillitis[2,11] and the 
ampullary carcinoma[25].
Regarding tumor resectability, radiologists should 
with small tumors, results in tumor-associated chronic 
pancreatitis. Many times, the pancreatic parenchyma 
distal to pancreatic adenocarcinoma is atrophic and 
low in signal intensity compared to normal pancreas, 
due to chronic inflammation, progressive fibrosis and 
diminished proteinaceous fluid of the gland[23,24]. In these 
cases, depiction of the tumor is poor on noncontrast T1-
weighted fat-suppressed images; nevertheless, arterial 
phase images are very helpful in the discrimination of the 
size and extent of pancreatic ductal adenocarcinomas, 
as tumors almost always enhance less than the adjacent 
chronically inflamed pancreas[23,24]. These imaging 
characteristics along with substantial increase of CA 19.9 
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Figure 1  Normal pancreas. Axial T2-weighted SS-ETSE (A), pre-contrast fat-suppressed T1-weighted (B) GRE and post-gadolinium fat-suppressed T1-weighted 
gradient echo images acquired in the arterial (C) and venous (D) phases of enhancement. The normal pancreas is high in signal intensity on T1-weighted images 
(B) due to the presence of aqueous protein in the pancreatic acini. A uniform capillary blush is apparent on the immediate post-gadolinium image (C). T2-weighted 
sequences allow the depiction of the pancreatic duct. SS-ETSE: Single-shot echo train spin echo; GRE: Gradient echo.
A B
C D
Figure 2  Pancreatic ductal adenocarcinoma. Axial post-gadolinium fat-suppressed T1-weighted images obtained in the arterial phase (A) and interstitial phase 
(B) image, and coronal maximum intensity projection image of MRCP (C). There is a hypovascular tumor arising in the pancreatic head (arrow, A) that obstructs the 
common bile duct and pancreatic duct (double duct sign). This sign is well depicted in the MRCP images (C). MRCP: Magnetic resonance cholangiopancreatography.
A B C
Al Ansari N et al . MRI of solid pancreatic nodules
evaluate certain MRI findings and describe them in the 
MRI report: (1) distant metastases, frequently to the 
liver, peritoneum, lung and paraortic lymph nodes; (2) 
infiltration of neighboring structures, including stomach, 
colon, spleen; (3) invasion of the peripancreatic arteries, 
including celiac trunk, hepatic artery, superior mesenteric 
artery; and (4) invasion of the peripancreatic veins, 
including portal and superior mesenteric vein[2,14,22,26].
State of the art MRI is suitable to detect and cha-
racterize focal ductal adenocarcinoma smaller than 1 
cm[2,21,22,27], which tend to appear as small non-contour-
deforming pancreatic lesions. Detection of this early 
manifestation of disease is difficult or impossible to 
identify with multiphasic current-generation CT[28,29]. 
Endoscopy ultrasound has been widely used in dete-
ction of clinically suspected pancreatic lesion; together 
with fine needle aspiration, it has been reported to 
be the best diagnostic method for small pancreatic 
neoplasms. Unfortunately this is an invasive and an 
operator-dependent-technique and is not yet widely 
used[30].
It is very important to differentiate adenocarcinoma 
from other benign and malignant entities, because the 
clinical management and prognosis varies according to 
the type of pathology[2,31]. Some lesions require surgery 
or imaging follow-up, whereas other lesions are clini-
cally irrelevant, not requiring further evaluation and/or 
treatment. 
BENIGN LESIONS THAT MAY SIMULATE 
DUCTAL ADENOCARCINOMA
Pancreatic lipomatosis
Pancreatic lipomatosis is a condition related to fatty 
infiltration/replacement of the pancreatic parenchyma, 
and is commonly seen in the elder, especially in obese 
patients. Involvement is normally diffuse but occasionally 
it may simulate a neoplastic lesion. The anterior aspect 
of the head of the pancreas is the most common location 
for pancreatic lipomatosis (Figure 4). 
The absences of mass effect, ductal or vascular 
displacement are important findings to establish the 
correct diagnosis.
MRI is highly specific for the detection of fat[32]. A 
moderate to marked signal loss in the out-of-phase 
relative to the in-phase images is distinctive of this con-
dition (Figure 4)[33]. Macroscopic fatty replacement of the 
pancreas will show high T1 and T2 signal intensity, and 
marked signal loss on fat-suppressed sequences[32-34].
Acute pancreatitis
Acute pancreatitis is defined as an acute inflammatory 
condition typically presenting with abdominal pain and 
elevation in pancreatic enzymes secondary mainly to 
alcoholism or cholelithiasis.
MRI is more sensitive than CT, supporting the use of 
MRI in the evaluation of patients with a nonconclusive 
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Figure 3  Pancreatic ductal adenocarcinoma. Axial T2-weighted single-shot echo train spin echo (A), pre-contrast fat-suppressed T1-weighted (B) gradient echo 
(GRE) and post-gadolinium fat-suppressed T1-weighted GRE images acquired in the arterial (C) and venous (D) phases of enhancement. There is a solid nodule in 
the head of the pancreas, which is more conspicuous in the pre-contrast and arterial phase T1-weighted images (B, arrow, C), consistent with ductal adenocarcinoma. 
Note that this lesion might be imperceptible on T2-weighted images (A) and venous phase images (D).
Al Ansari N et al . MRI of solid pancreatic nodules
CT or to differentiate pure inflammatory condition from 
neoplastic lesion of the pancreas.
The acutely inflamed pancreas shows either focal 
or diffuse enlargement of the parenchyma, with signal 
intensity comparable to that of normal pancreatic tissue 
in non-complicated mild to moderate pancreatitis. 
Peripancreatic fluid is an important sign visualized in 
acute pancreatitis, best displayed on fat-suppressed 
T2-weighted sequences, seen as high signal in a back-
ground of intermediate to low-signal pancreas and fat 
(Figure 5)[2,35,36].
Chronic pancreatitis
Chronic pancreatitis is defined as a continuous or 
relapsing, chronic, inflammatory process of the pan-
creas, characterized by permanent morphologic changes 
and typically leads to diminishing of function. Distinction 
between focal pancreatitis and adenocarcinoma may 
be challenging because both entities may result in focal 
enlargement of the pancreatic head, atrophy of the tail 
of the pancreas and obliteration of the fat plane around 
the superior mesenteric artery. Ductal adenocarcinoma 
arising in the pancreatic head may cause obstruction 
of the CBD and pancreatic duct, with the MRCP app-
earance of a “double duct sign”. This sign can be also 
appreciated, although less commonly, in patients with 
focal pancreatitis. 
Focal chronic pancreatitis and adenocarcinoma 
may display comparable signal intensity changes of 
the enlarged region of pancreas on noncontrast T1- 
and T2-weighted images, including mild hypointensity 
on T1-weighted images and heterogeneous and mild 
hyperintensity on T2-weighted images.
On arterial phase images, focal chronic pancreatitis 
usually displays heterogeneous enhancement and may 
show signal voids from cysts and/or calcifications with 
no evidence of a definable mass. In this setting, the 
focally enlarged region of the pancreas preserve the 
glandular feathery texture, comparable to the remaining 
pancreas[37]. Conversely, in ductal adenocarcinoma, the 
focally enlarged region of the pancreas loses its usual 
anatomic detail.
Diffuse low T1 signal intensity and hypovascularity 
of the entire pancreas, including the region of focal 
enlargement, are distinctive for chronic pancreatitis. 
In the setting of ductal adenocarcinoma, the tumor 
enhances less than the adjacent chronically inflamed 
pancreatic parenchyma[38]. 
Several features favor a diagnosis of focal pancreatitis, 
including: (1) non-dilated or smoothly tapering pancreatic 
and bile ducts coursing through the mass (“duct 
penetrating sign”)[38]; (2) parenchymal calcifications 
(seen as signal voids); (3) pancreatic duct beading 
and varying caliber; and (4) side branch dilatation. 
Instead, abrupt interruption of a smoothly dilated main 
pancreatic duct, minimal side-branch dilatation, upstream 
pancreatic atrophy and a high ratio of duct caliber to the 
pancreatic gland width are features typically observed in 
adenocarcinoma (Figure 2)[39].
A previous investigation evaluated the accuracy 
of MRI in the differentiation between ductal adeno-
carcinoma and chronic pancreatitis, in patients with focal 
pancreatic mass[37]; in this study, MR technique with the 
use of fat-suppressed T1-weighted 3D-GRE sequence 
was able to differentiate ductal adenocarcinoma from 
chronic pancreatitis with a sensitivity and specificity of 
93% and 75%, respectively. The most critical finding for 
ductal adenocarcinoma of the pancreas was a relative 
delineation of the mass compared to the background 
pancreatic parenchyma. On the other hand, the most 
critical finding of chronic pancreatitis was an imprecise 
delineation with a mildly increased signal intensity and 
enhancement compared with the background pancreatic 
parenchyma on portal-venous phase images. These 
features reflect a more progressive enhancement of 
inflammatory tissue compared to ductal adenocarcinoma 
from arterial phase to portal-venous images. A further 
useful imaging feature is effacement of the fine, lobular 
architectural pattern of the pancreas in pancreatic 
adenocarcinoma[37]. 
The encasement of the celiac axis, superior mesen-
teric artery, lymphadenopathy and liver metastases 
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Figure 4  Pancreatic lipomatosis. Axial in-phase (A) and out-of-phase (B) T1-weighted GRE images. There is a focal fat infiltration in the region of the pancreatic 
head (arrows), only noticeable in the out-of-phase images, which is diagnostic for this entity. Focal fat infiltration is a benign condition that can simulate pancreatic 
adenocarcinoma especially on CT. GRE: Gradient echo; CT: Computed tomography.
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establish the diagnosis of ductal adenocarcinoma[26,40], 
with liver metastases representing the definitive 
distinction.
OTHER SOLID PANCREATIC TUMORS 
WITH EPITHELIAL AND ENDOCRINE 
ORIGIN THAT MIGHT SIMULATE DUCTAL 
ADENOCARCINOMA
ACC
ACC is a rare primary tumor of the exocrine gland of 
the pancreas, and although acinar cells comprise most 
of the pancreatic parenchyma, ACC represents only 
1% of all exocrine pancreatic cancers. Tumors generally 
occur between the fifth and seventh decades[2]. It is 
defined as a carcinoma exhibiting pancreatic enzyme 
secretion by neoplastic exocrine cells, and its clinical 
presentation is usually related to either the local effects 
of the tumor or to metastases[41]. Presenting symptoms 
are frequently nonspecific. “Lipase hypersecretion 
syndrome” is related to hypersecretion of lipase by the 
ACC, which may result in subcutaneous fat necrosis, 
bone infarcts, and polyarthritis[42,43]. Hypoglycemia as a 
presenting symptom has also been observed in some 
patients. 
These cancers are generally exophytic, oval or round, 
well marginated, and hypovascular. Small tumors are 
usually solid, whereas larger tumors almost invariably 
contain cystic areas representing regions of necrosis, 
hemorrhage, and occasionally amorphous intratumoral 
calcifications, seen as signal voids[38,39]. 
These tumors are frequently uniformly or partially 
well-defined, with thin, enhancing capsules, and 
enhance less than the adjacent normal background pan-
creas[38,39]. These tumors are predominantly low in signal 
intensity on T1-weighted images and iso- to moderately 
hyperintense on T2-weighted images. 
ACC should always be considered when a large 
pancreatic mass with typical imaging is found a solid 
mass with variably sized central cystic areas or cystic 
masses[2,43-45]. The tumor marker CA 19.9, which is 
generally increased in pancreatic adenocarcinoma, is 
rarely elevated in ACC.
UNCERTAIN ORIGIN
SPT 
SPT of the pancreas is an uncommon, low-grade epit-
helial malignancy of the exocrine pancreas that most 
often appears in young female patients[2,20,46], and 
accounts for about 1% to 2% of all pancreatic tumors[47].
This tumor is typically benign and is found mainly 
in young women between the 2nd and 3rd decades 
of life. This age presentation is rarely seen in ductal 
adenocarcinoma. This tumor shows a predilection for 
African-American and Asian women, despite rare cases 
having been reported in children and men. Malignant 
degeneration may occur, however most SPTs show 
benign behavior[48,49]. Complete surgical removal is the 
treatment of choice. Metastasis is rare but local recurr-
ence has been described. The prognosis is excellent after 
resection.
The mass occurs most frequently in the head or 
tail. SPT is often discovered incidentally and appears as 
a large well-demarcated and encapsulated pancreatic 
mass, surrounded by a marginal thick capsule and with 
variable relative amounts of intralesional solid, cystic 
and hemorrhagic components. The peripheral capsule 
is often present and seen on MRI, with an incidence of 
95%-100%[48]. Vascular encasement is exclusively seen 
in malignant types.
MR imaging characteristically shows a well-defined 
lesion with heterogeneous T1- and T2-weighted 
signal intensity, reflecting the complex nature of the 
mass. Regions of high T1 and low or inhomogeneous 
T2 signal intensity may be seen and are related with 
blood products and may help to differentiate SPTs from 
endocrine tumors, whose cystic components gene-
rally are not hemorrhagic and therefore not typically 
possessing moderately increased T1 signal intensity. 
Furthermore, the peripheral areas of SPTs are not 
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Figure 5  Acute pancreatitis. Axial in-phase (A) T1-weighted GRE image and arterial phase (B) fat-suppressed T1-weighted GRE image (B) in a patient with elevated 
amylase. There is a nodular area in the uncinate process showing mild T1-weighted hypointensity due to edema, however showing arterial enhancement (arrow, B) 
and with preservation of marbled pancreatic texture. This was compatible with focal acute pancreatitis. GRE: Gradient echo.
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hypervascular, which is characteristically observed in islet 
cell tumors[2,46,48,49] (Figure 6).
PANCREATIC NEUROENDOCRINE 
TUMORS
Pancreatic neuroendocrine tumors (NET) were previously 
called islet cell tumor, as it was believed that they derived 
from the islets of Langerhans. Recent evidence suggests 
that these tumors arise from pluripotential stem cells in 
the ductal epithelium[50]. They account for 1%-2% of all 
pancreatic neoplasms. The majority NETs are sporadic, 
but association with syndromes such as with Wermer 
syndrome, neurofibromatosis type 1, von Hippel-
Lindau syndrome, and tuberous sclerosis have been 
reported. NETs are classified into functioning and non­
functioning tumors. Functioning tumors may clinically 
present with an endocrine malfunction subsequent to 
hormone secretion[51]. The diagnosis of functioning NETs 
is almost always established biochemically, and the role 
of imaging is to depict the precise location of the tumor. 
Insulinomas and gastrinomas are the most common 
pancreatic NETs, followed by non-functional or untyped 
tumors.
Non-functional tumors account for 15%-20% of 
pancreatic NETs and tend to be symptomatic due to 
large tumor mass or metastatic disease. Functioning 
tumors manifest early in the course of disease when 
they are small, due to the clinical manifestations of 
excessive hormone secretion.
Malignancy cannot be determined based on the 
histological appearance of pancreatic NETs, instead 
it is established by the coexistence of metastases or 
local invasion. The liver is the most affected organ for 
metastatic spread.
Insulinomas are usually benign tumors, whereas 
gastrinomas are malignant in nearly 60% of cases. 
Nonfunctioning tumors are malignant in most cases.
Tumor morphology is variable. Small tumors are 
usually solid and homogeneous, whereas larger tumors 
are usually heterogeneous with cystic degeneration and 
calcifications.
On MRI, NETs are moderately low T1 and inter-
mediate to high signal intensity on T2-weighted fat-
suppressed images[52]. These tumors are typically highly 
hypervascular and therefore they enhance intensely on 
arterial/pancreatic phase after contrast administration. 
This distinctive feature must be interpreted cautiously, 
as although they may enhance more rapidly and avidly 
than the background pancreas, they may also appear 
iso-intense during the arterial phase, as the normal 
pancreatic parenchyma is also highly vascularized 
(Figure 7).
Insulinomas are usually seen as small tumors (< 
2 cm), with intense and homogeneous enhancement 
on arterial phase images, whereas gastrinomas most 
commonly are larger lesions (3-4 cm approximately), 
with peripheral ring-like enhancement on arterial 
phase images[2,53]. Gastrinomas generally occur in a 
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Figure 6  Solid pseudopapillary tumor. Coronal (A) and axial fat-suppressed (B) T2-weighted SS-ETSE, pre-contrast fat-suppressed T1-weighted (C) GRE 
and post-gadolinium fat-suppressed T1-weighted GRE images acquired in the arterial (D) and venous (E) phases of enhancement. A large well-demarcated and 
encapsulated mass is located in the tail and body of the pancreas. The mass shows heterogeneous signal intensity, with cystic (arrows, A and B) and hemorrhagic 
areas (arrow, C). The solid component of the lesion shows progressive enhancement over time. A mass with these characteristics, appearing in a young patient is 
most likely related with solid pseudopapillary tumor. SS-ETSE: Single-shot echo train spin echo; GRE: Gradient echo.
Al Ansari N et al . MRI of solid pancreatic nodules
distinctive location, termed the gastrinoma triangle, 
bordered superiorly by the confluence of the cystic and 
CBDs; inferiorly, by the second and third portions of the 
duodenum; and medially, by the neck and body of the 
pancreas.
The likelihood of malignancy rises in parallel with 
tumor size, and tumors larger than 5 cm are frequently 
malignant. Even when malignant, these tumors are 
slow-growing and the prognosis is better than for ductal 
adenocarcinoma[18,54]. Metastases to lymph nodes and 
solid organs may have an enhancement pattern similar 
to that of the primary tumor (Figure 8).
It is essential to distinguish pancreatic NETs from 
other neoplasms, especially from ductal adenocar-
cinoma, as the prognosis and treatment options are 
usually substantially different for these two entities.
Features that discriminate most pancreatic NETs from 
pancreatic adenocarcinoma include the high T2 signal, 
increased homogeneous enhancement on arterial phase 
images, hypervascular liver metastases, and absence of 
pancreatic duct obstruction or vascular encasement[53]. 
On the other hand, venous thrombosis, peritoneal, and 
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Figure 7  Pancreatic neuroendocrine tumor. Axial fat-suppressed T2-weighted SS-ETSE (A), pre-contrast fat-suppressed T1-weighted (B) GRE and arterial phase 
fat-suppressed T1-weighted GRE image (C). There is a small solid lesion in the tail of the pancreas (arrow, A-C), showing moderate signal intensity on T2-weighted 
images (arrow, A) and demonstrates marked enhancement in the arterial phase of enhancement (arrow, C). This was an insulinoma. SS-ETSE: Single-shot echo train 
spin echo; GRE: Gradient echo.
Al Ansari N et al . MRI of solid pancreatic nodules
Figure 8  Pancreatic neuroendocrine tumor and liver metastases. Axial T2-weighted SS-ETSE (A), diffusion weighted images (b = 500) (B) and post-gadolinium 
fat-suppressed T1-weighted GRE images acquired in the arterial (C) and venous (D) phase of enhancement. A large mass is seen arising in the body and tail of the 
pancreas, showing moderate signal intensity on T2-weighted images (A) and restriction to diffusion (B). This lesion shows hypervascular characteristics (C). This 
mass was diagnosed as poorly differentiated neuroendocrine tumor. Note that the liver metastases show similar signal characteristics on T2- and diffusion-weighted 
images and demonstrate the characteristic arterial wash-in (arrow, C) and late washout (D) seen with neuroendocrine tumor metastases. SS-ETSE: Single-shot echo 
train spin echo; GRE: Gradient echo.
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regional node enlargement are distinguishing features of 
pancreatic ductal adenocarcinoma, usually not seen in 
NETs.
MESENCHYMAL TUMORS 
Mesenchymal neoplasms of the pancreas are rare, 
accounting for 1% to 2% of all pancreatic tumors[55,56]. 
They derive from various connective tissue components 
and are classified according to their histologic origin.
Primary pancreatic lymphoma, although unusual, 
is the most common malignant mesenchymal tumor 
appearing in the pancreas. Benign mesenchymal adipose 
tissue tumors, such as lipomas or teratomas are extre-
mely rare and show diagnostic features on MRI, with 
homogeneous encapsulated mature fat or with fat­fluid 
levels, respectively[55,56]. Other mesenchymal tumors, 
such as lymphangiomas, leiomyoma, leiomyosarcoma, 
schwannoma, hemangioma, or hemangioendothelioma, 
have also been reported; however, they are exceedingly 
rare, appearing described only in the form of isolated 
case reports.
Pancreatic lymphoma
Non-Hodgkin lymphoma may involve peripancreatic 
lymph nodes or may directly infiltrate the pancreas. 
Peripancreatic lymph nodes show low to intermediate 
signal intensity on T1-weighted fat-suppressed images, 
which permit to be distinguished from the normal 
pancreas that shows high signal intensity[57].
Primary pancreatic lymphoma is a rare entity, 
accounting for less than 2% of extranodal lymphomas 
and 0.5% of pancreatic tumors[58].
Pancreatic lymphoma has a better prognosis than 
pancreatic ductal adenocarcinoma, as first-line treat-
ment with chemotherapy is normally effective, allowing 
long-term disease regression or remission. Surgery is 
usually not required.
Two morphologic patterns are recognized: focal 
and diffuse form[59]. The focal form occurs in the 
pancreatic head in 80% of the cases and may mimic 
adenocarcinoma.
On MRI, lymphoma shows low T1 and intermediate 
T2 signal intensity. Several features may help discrimi-
nate pancreatic lymphoma from ductal adenocarcinoma 
such as the presence of a bulky confined tumor in the 
pancreatic head with absent or minimal main pancreatic 
duct dilatation, enlarged lymph nodes below the 
level of the renal vein, and a tendency to noninvasive 
tumor growth, which are characteristic for pancreatic 
lymphoma and atypical for pancreatic ductal adenoc-
arcinoma (Figure 9). Vascular invasion is also less 
commonly seen in lymphoma[2]. Additionally, CA 19.9 
levels are usually not elevated in primary or secondary 
pancreatic lymphoma.
NONPANCREATIC TUMOR LESION
Metastases
Metastases to the pancreas may be the result of direct 
invasion or hematogenous spread. Direct invasion from 
stomach and transverse colon carcinoma and GIST 
tumors are rare, but the most common forms of direct 
extension.
Metastases derive most frequently from renal cell 
carcinoma and lung cancer followed by breast, colon, 
prostate and malignant melanoma.
Three morphological patterns of metastatic involve-
ment of the pancreas have been described: solitary 
lesion (50%-70% of cases), multifocal (5%-10%), and 
diffuse (15%-44%)[59].
Metastases generally show low T1 and mildly high 
T2 signal intensity. The enhancement of the majority 
of metastases follows a ring pattern, with a variable 
degree of enhancement depending on the angiogenic 
properties of the primary neoplasm (Figure 10)[60]. 
Renal cancer metastases resemble the appearance 
of NETs. Melanocytic melanoma metastases may display 
high T1 signal due to the paramagnetic properties of 
melanin pigment.
Ductal obstruction is uncommon, even with larger 
tumors, which is an important feature distinguishing 
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Figure 9  Pancreatic lymphoma. Pre-contrast fat-suppressed axial T1-weighted gradient - echo images (A) and acquired in the arterial phase after gadolinium 
injection (B). There is a large hypointence and hypovascular mass (arrows) localized in the pancreatic head, however showing no significant duct dilatation. There was 
evidence of enlarged lymph nodes. This mass was diagnosed as pancreatic lymphoma.
A B
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Figure 11  Intra-pancreatic splenule. Axial T2-weighted SS-ETSE (A), pre-contrast fat-suppressed T1-weighted (B) GRE and post-gadolinium fat-suppressed T1-
weighted GRE images acquired in the arterial (C) and venous (D) phases of enhancement. There is a well-marginated and lobulated round intra-pancreatic splenule 
(arrows, A and B) that shows isointense signal to the pancreas on T2- and T1-weighted images (A and B). This nodule is hypointense compared to the background 
pancreas on the precontrast T1-weighted image (B) and demonstrates lesser enhancement relative to the pancreas on the arterial phase (C) and hepatic venous 
phase (D). The enhancement pattern was homogenous on the postgadolinium images and similar to that of the pancreas. SS-ETSE: Single-shot echo train spin echo; 
GRE: Gradient echo.
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Figure 10  Solitary pancreatic metastasis. Axial T2-weighted SS-ETSE (A) and post-gadolinium fat-suppressed T1-weighted GRE images acquired in the arterial (B), 
venous (C) and interstitial (D) phases of enhancement. There is a nodular lesion in the pancreatic body showing moderate signal intensity on T2-weighted images (arrow, 
A) and showing hypovascular characteristics, with no pancreatic duct dilatation. These are typical features of a solitary pancreatic metastasis (arrows). Note additional 
splenic metastases (lung cancer). SS-ETSE: Single-shot echo train spin echo; GRE: Gradient echo.
Al Ansari N et al . MRI of solid pancreatic nodules
from pancreatic ductal adenocarcinoma[2,59].
INTRAPANCREATIC SPLENULE
The presence of accessory splenules may arise within 
the parenchyma of solid organs, notably the pancreas. 
Intrapancreatic splenule is a somewhat uncommon 
location for splenules. These lesions typically are < 2 
cm in size and are located within 3 cm of the tip of the 
pancreatic tail[55]. The presence of a well marginated 
rounded mass located in the distal tail of the pancreas 
with signal intensity features comparable to those of 
the spleen on all MR sequences suggests the diagnosis 
of intrapancreatic accessory spleen (Figure 11). A 
distinctive feature of these masses is that when greater 
than 2 cm they may exhibit serpiginous enhancement 
on arterial phase images, as typically seen in the 
spleen[61]. Other entities may simulate the signal 
intensity and post-gadolinium enhancement features of 
intrapancreatic splenules, and DWI and SPIO-enhanced 
MRI can be used to characterize the lesion and to 
establish the definite diagnosis[61,62].
CONCLUSION
In addition to pancreatic ductal adenocarcinoma other 
solid pancreatic lesions occur. Many of the above-
described tumors may be diagnosed with relatively 
high specificity employing MRI. The radiologist must be 
familiar with their MRI appearance to correctly diagnose 
them, or suggest them in the differential diagnosis 
when appropriate, since it may change substantially 
the approach, prognosis and patient management. 
We have described specific features that may aid in 
the discrimination from ductal adenocarcinoma and 
establish the correct diagnosis.
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